drug
EVEROLIMUS
Marketedupdated 5mo agoby Novugen Pharma (Malaysia) Sdn Bhd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugeverolimus SR36 co-mentions · 24 sources
- drugeverolimus ODT36 co-mentions · 24 sources
- drugZortress36 co-mentions · 24 sources
- tagApproval16 co-mentions · 8 sources
- tagAdCom15 co-mentions · 11 sources
- tagPMA Approval15 co-mentions · 11 sources
- tagSmall Molecule8 co-mentions · 8 sources
- companyPar Pharmaceutical Inc5 co-mentions · 5 sources
all catalysts(6)
approval · 6
Mar 5, 2021
approval
EVEROLIMUS — FDA approval
EVEROLIMUS
→
Jun 22, 2023
approval
EVEROLIMUS — FDA approval
EVEROLIMUS
→
Jun 22, 2023
approval
EVEROLIMUS — FDA approval
EVEROLIMUS
→
Jun 22, 2023
approval
EVEROLIMUS — FDA approval
EVEROLIMUS
→
Jan 9, 2026
approval
EVEROLIMUS — FDA approval
EVEROLIMUS
→
Mar 6, 2026
approval
EVEROLIMUS — FDA approval
EVEROLIMUS
→
Trials studying EVEROLIMUS
- phase3Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- phase3Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- —REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia
- phase3Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- phase2A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
- N/AHybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions
- phase1Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer
- phase2A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 1, 2028
~1.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Jul 1, 2028method-of-use (U-1681)US 90062241.7y
- Jul 1, 2028method-of-use (U-1681)US 90062241.7y
- Jul 1, 2028method-of-use (U-1681)US 90062241.7y
- Jul 1, 2028method-of-use (U-1681)US 90062241.7y
- May 1, 2026patentUS 8410131*PED
- May 1, 2026patentUS 8410131*PED
- May 1, 2026patentUS 8410131*PED
- May 1, 2026patentUS 8410131*PED
- Nov 1, 2025method-of-use (U-1368)US 8410131
- Nov 1, 2025method-of-use (U-1368)US 8410131
- Nov 1, 2025method-of-use (U-1368)US 8410131
- Nov 1, 2025method-of-use (U-1368)US 8410131
News(3)
- FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issuesITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns.biospace · 1mo ago
- STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatmentThe FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.stat · 1mo ago
- Opinion: I’m a heart transplant recipient. I’m haunted by ‘ghost approval’ for medication I need to survive“On paper, I have insurance coverage. In real life, I don’t have access. That’s what I call ‘ghost approval,’” writes patient advocate Payton Herres.stat · 4mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that